BİR YÜCEL, K. Et Al. 2022. Nivolumab-ipilimumab combination therapy-induced seronegative encephalitis; rapid response to steroid plus intravenous immunoglobulin (IVIG) treatment. JOURNAL OF ONCOLOGY PHARMACY PRACTICE .

BİR YÜCEL, K., SÜTCÜOĞLU, O., YAZICI, O., YILDIZ, Y., ŞENOL, E., & ÜNER, A., (2022). Nivolumab-ipilimumab combination therapy-induced seronegative encephalitis; rapid response to steroid plus intravenous immunoglobulin (IVIG) treatment. JOURNAL OF ONCOLOGY PHARMACY PRACTICE .

BİR YÜCEL, KADRİYE Et Al. "Nivolumab-ipilimumab combination therapy-induced seronegative encephalitis; rapid response to steroid plus intravenous immunoglobulin (IVIG) treatment," JOURNAL OF ONCOLOGY PHARMACY PRACTICE , 2022

BİR YÜCEL, KADRİYE B. Et Al. "Nivolumab-ipilimumab combination therapy-induced seronegative encephalitis; rapid response to steroid plus intravenous immunoglobulin (IVIG) treatment." JOURNAL OF ONCOLOGY PHARMACY PRACTICE , 2022

BİR YÜCEL, K. Et Al. (2022) . "Nivolumab-ipilimumab combination therapy-induced seronegative encephalitis; rapid response to steroid plus intravenous immunoglobulin (IVIG) treatment." JOURNAL OF ONCOLOGY PHARMACY PRACTICE .

@article{article, author={KADRİYE BİR YÜCEL Et Al. }, title={Nivolumab-ipilimumab combination therapy-induced seronegative encephalitis; rapid response to steroid plus intravenous immunoglobulin (IVIG) treatment}, journal={JOURNAL OF ONCOLOGY PHARMACY PRACTICE}, year=2022}